<DOC>
	<DOCNO>NCT02180464</DOCNO>
	<brief_summary>Proof-of concept study competitively investigate antipsoriatic efficacy safety LAS41004 formulation vs active control No formal study hypothesis , descriptive evaluation ( PoC ) .</brief_summary>
	<brief_title>A Intra-individual Comparison Investigate Efficacy Safety LAS41004 Formulation Mild Moderate Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion Criteria ( main ) : mild moderate stable chronic plaquetype psoriasis least two symmetrical lesion treatment area 20 300 cm² TSS ≥ 6 ; female volunteer childbearing potential* must agree use appropriate reliable method contraception write informed consent obtain . Exclusion Criteria ( main ) : severe form psoriasis form psoriasis chronic plaque psoriasis , treatment locally act medication might counter influence trial aim within 2 week precede treatment phase trial trial ; treatment systemic medication might counter influence trial aim phototherapy/PUVA within 4 week precede treatment phase trial trial ; treatment vitamin A supplement ; treatment biologics within 3 month precede treatment phase trial trial , case ustekinumab , within 6 month ; treatment immunosuppressive medication within 6 month precede treatment phase trial trial ; know allergic reaction , irritation hypersensitivity active ingredient contraindication accord summary product characteristic ( SmPC ) active comparator : pregnancy nursing ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>psoriasis , topical</keyword>
</DOC>